Get the app!
Back to Trades
Buy4

Kailera Therapeutics, Inc.

KLRA

Total Value
$25.0M
Net $25.0M bought
Purchases
$25.0M
1 transaction

Company Information

Ticker Symbol
KLRA
CIK
0002096997

Insider Information

Role
Insider
Location
BOSTON, MA

Filing Details

Filing Date
Apr 20, 2026
Transaction Date
Apr 20, 2026
Accession Number
0001193125-26-164389
Form Type
4
Net Trading Amount
$25.0M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Apr 20, 2026Common Stock16,875,000C
Apr 20, 2026Common Stock4,145,768C
Apr 20, 2026Common Stock1,562,500$16.00Purchase$25.0M

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Apr 20, 2026Derivative16,875,000C
Apr 20, 2026Derivative4,145,768C

Footnotes

  1. (F1)Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  2. (F2)Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  3. (F3)Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").
  4. (F4)Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.